Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7555861 | 1.00 | PARP1 (0.58) | PARP1HPGDPTPN1POLBMAOA | |
| SCHEMBL7556560 | 0.86 | HPGD (0.52) | PARP1HPGDPTPN1POLBMAOA | |
| SCHEMBL7556551 | 0.86 | HPGD (0.52) | PARP1HPGDPTPN1POLBMAOA | |
| SCHEMBL8685704 | 0.82 | PARP1 (0.72) | PARP1HPGDPTPN1POLBMAOA | |
| SCHEMBL8809748 | 0.82 | PARP1 (0.72) | PARP1HPGDPTPN1POLBMAOA | |
| SCHEMBL7554110 | 0.82 | PARP1 (0.59) | PARP1HPGDPTPN1POLBMAOA | |
| SCHEMBL7554075 | 0.82 | PTPN1 (0.57) | PARP1HPGDPTPN1POLBMAOA | |
| SCHEMBL7554119 | 0.82 | PARP1 (0.59) | PARP1HPGDPTPN1POLBMAOA | |
| SCHEMBL7554083 | 0.82 | PTPN1 (0.57) | PARP1HPGDPTPN1POLBMAOA | |
| SCHEMBL7556256 | 0.80 | PTPN1 (0.59) | HPGDPTPN1POLBMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | CHIN ALLISON C (US) | 2002-08-22 | — | — | US | disclosed |
| US-6372742-B1 | TELOMERASE ENZYME INHIBITORS AND ANTICANCER AGENTS | GERON CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1109808-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002394-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | TERT, INMT, POT1 | PARP1 76/4885HPGD 1197/4885PTPN1 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.